10-Q Impact 7/10 Earnings

$AWHL · Aspira Women's Health Inc.

November 16, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Aspira Women's Health filed its 10-Q for the quarter ended September 30, 2026. Revenue fell 18.4% YoY to $1.9M, with OvaSuite test volume down 13% to 14,870 tests. The company reported net income of $339,000 for the quarter, driven by a $1.9M non-cash gain on warrant liability fair value, but a nine-month net loss of $1.4M. Cash and cash equivalents collapsed to $12,000 from $1.755M at year-end, and the company disclosed a going-concern warning.

  • Cash and cash equivalents fell to $12,000 from $1.755M at December 31, 2025.
  • Q3 revenue of $1.9M declined 18.4% YoY; OvaSuite test volume fell 13% to 14,870.
  • Nine-month net loss was $1.4M, improved from $9.4M a year earlier.
  • Q3 net income of $339,000 stemmed from a $1.9M non-cash warrant liability fair-value gain.
  • Working capital deficit was with an accumulated deficit of $545.6M.
PeriodQ3 FY2026
Revenue$1.9M
Revenue YoY-18.4%
EPS$0.01
Net income$339,000
Gross margin53.8%
Op. margin-64.3%

Price data unavailable.

A diagnostics company with $12,000 in cash and a going-concern warning faces an acute liquidity crisis despite a headline quarterly profit.

Aspira's shrinking OvaSuite volume contrasts with broader diagnostics growth, underscoring its liquidity-driven survival challenge.

Going-concern disclosure cites $12,000 cash, $4.2M working capital deficit, and expected continued losses and negative operating cash flow for the rest of 2026.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →